CN112345762A

CN112345762A - Application of KNG1 protein expressed by lung cancer patient alveolar lavage fluid

Info

Publication number: CN112345762A
Application number: CN201910727804.4A
Authority: CN
Inventors: 张曼; 王巍伟
Original assignee: Beijing Shijitan Hospital
Current assignee: Beijing Shijitan Hospital
Priority date: 2019-08-08
Filing date: 2019-08-08
Publication date: 2021-02-09

Abstract

The present invention provides a means for detecting alveolar lavage fluid protein, and successfully detects the expression of Kininogen 1(KNG1) in alveolar lavage fluid of normal and lung cancer patients. The invention proves the expression characteristics of KNG1 in the alveolar lavage fluid of normal persons and lung cancer patients through research, and proves that the alveolar lavage fluid KNG1 has diagnostic value on the disease conditions of the patients.

Description

Application of KNG1 protein expressed by lung cancer patient alveolar lavage fluid

Technical Field

The invention relates to detection of alveolar lavage fluid protein of normal people and lung cancer patients, and confirms that the content of KNG1 in alveolar lavage fluid of the lung cancer patients is obviously higher than that of normal people.

Background

Lung cancer is the leading cause of cancer death worldwide, accounting for over 1/4 of all cancer deaths. Each year, lung cancer causes 40 million deaths. Currently, the primary means of lung cancer treatment remains surgical resection, but once the disease progresses to the metastatic stage, surgical resection treatment is often ineffective and the prognosis for patients with advanced stages is poor. Chemotherapy generally fails to treat patients with metastatic lung cancer, the 5-year survival rate of patients is less than 15%, and no clear optimal method for treating lung cancer exists at present. The low survival rate of lung cancer patients is due to the inability to make early diagnosis and thus effective surgical treatment. Therefore, means for early detection of lung cancer is urgently needed to reduce mortality.

Kininogen 1(KNG1) is a cysteine protease inhibitor that inhibits endothelial cell proliferation and angiogenesis. KNG1 has been detected using mass spectrometry and KNG1 has been identified as a serum biomarker for advanced colorectal adenoma and colorectal carcinoma. In addition to saliva available for oral squamous cell carcinoma detection and monitoring of high-risk individuals, the correlation of the levels of KNG1 in lung cancer patients with disease remains to be assessed. The invention detects the expression of the KNG1 protein in alveolar lavage fluid, verifies the value of the KNG1 protein to lung cancer diagnosis, and provides the application of the KNG1 protein expressed by the human alveolar lavage fluid.

Disclosure of Invention

The invention aims to provide a detection mode of human alveolar lavage fluid expression protein.

Preferably, the human alveolar lavage fluid is alveolar lavage fluid of normal and lung cancer patients.

Preferably, the protein is KNG 1.

The inventor firstly collects alveolar lavage fluid of normal people and lung cancer patients, then detects the alveolar lavage fluid by an ELISA method, analyzes the result with the disease condition of the patients and confirms that KNG1 in the alveolar lavage fluid has correlation with lung cancer.

In order to make the aforementioned and other objects, features and advantages of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.

Drawings

FIG. 1 is a graph of the expression of alveolar lavage KNG1 in normal and lung cancer patients.

Detailed Description

Example 1Alveolar lavage fluid collection

Patients were first locally anesthetized with 2% lidocaine and then bronchoscoped using a fiberoptic bronchoscope (Olympus expera BF 240). To prevent any possibility of blood contamination, the biopsy or brush specimen collection needs to be flushed. The disease collateral bronchus was rinsed twice with 50ml of sterile saline, and then the solution was slowly placed in a glass tube and placed in ice water for rinsing. 40ml of alveolar lavage fluid was recovered. After separation, the lavage solution was immediately spun at 1500g for 10 minutes and the supernatant was then frozen at-80 ℃.

Example 2Detection of KNG1 protein

The concentration of alveolar lavage fluid KNG1 was measured using an enzyme-linked immunosorbent assay kit. Alveolar lavage fluid samples were diluted 100-fold and 200-fold and incubated in elisa assay plates. The optical density was measured at 450nm using a model 680 microplate analyzer (BIO-RAD). The concentration of the standard sample and the corresponding optical density value are used to draw a standard curve for each plate. Meanwhile, positive and negative controls are adopted in the test to improve the effectiveness of the method.

Although the present invention has been described with respect to the preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

Claims

1. Detecting proteins in human alveolar lavage fluid.

2. The method of claim 1, wherein said human is a normal human and a lung cancer patient.

3. The method of claim 1, wherein said alveolar lavage fluid is alveolar lavage fluid from a normal human or a lung cancer patient.

4. The method of claim 1, wherein said protein is KNG1 protein.

5. The method of claim 4, wherein KNG1 expression is significantly elevated in alveolar lavage fluid from a lung cancer patient compared to normal and is associated with a disease state in the patient.